Since abnormalities in the homologous recombination deficiency (HRD)-related genes are observed in pancreatic cancer, clinical trials to verify the efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitors have been conducted in pancreatic cancer patients with germline mutations in BRCA1/2 [45,46,47,48]. The gene discussed is BRCA1; the disease is pancreatic neoplasm.